Adaptimmune Therapeutics plc (ADAP) shares are trading at higher $9.42 and the avg recommendation for the stock is Moderate Buy. while the current analyst price target stands at $12.67.
To add more color to this target, the company’s high over the last year is $13.40 and the low is $0.71. Over the last 52 weeks, ADAP is up 411.96% while the S&P 500 is up 12.41%. The catalyst for this interesting swing was the company’s recent earnings report.
A Notable Earnings Report
In the last quarter, ADAP reported a profit of $30.75 million. Adaptimmune Therapeutics plc also saw revenues increase to $0.5 million. In addition, ADAP has free cash flow of -$8.52 million as of 06-2020. The company’s EBITDA came in at -$28.1 million which compares well with its peers.
ADAP Return on Equity (ROE) is -58.60%, and its Return on Assets is -42.70%. All told, it is clear that, ADAP needs to be on your watchlist.
Find out when ADAP reaches critical levels. Subscribe to OracleDispatch.com Right Now by entering your Email in the box below.
Of course, we must look beyond the financials and question how well those numbers represent the sustainable earnings power of the business. Investors need to know how sustainable this current run. ADAP has a short ratio of 4.20 and outstanding shares of 137.12M.
ADAP has seen increased volume after this news and investors are putting their support behind the value proposition. Furthermore, 10-day volume stands at 0.5 million and more growth is possible in the weeks ahead. Traders will also note the company’s earnings per share came in at -1.10. Adaptimmune Therapeutics plc ADAP also noted assets of $512.2 million at the end of the last quarter. Investors should also keep an eye on sector updates as ADAP has historically followed its peers on positive news.
All told, Adaptimmune Therapeutics plc ADAP has strung together solid data and demonstrated underlying fundamentals. At its current valuation, ADAP represents an interesting risk/reward case. Traders should stay tuned to see if this recent report will push the stock to test recent resistance levels.
Adaptimmune Therapeutics plc ADAP is now commanding a market cap of 1.49B and a float of 11.20M. ADAP is increasing its credibility in this sector and that could lead to more upside down the line. Sign-up for continuing coverage on shares of ADAP stock, as well as other hot stock picks, get our free newsletter today and get our next breakout pick!
Disclosure: we hold no position in ADAP, either long or short, and we have not been compensated for this article.